(Q38002006)

26 August 2017

Cardioprotective effects of incretin during ischaemia-reperfusion (English)

1 reference

26 August 2017

Kroekkiat Chinda

1

1 reference

26 August 2017

Siriporn Chattipakorn

series ordinal

2

1 reference

26 August 2017

Nipon Chattipakorn

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

11 April 2012

1 reference

Diabetes and Vascular Disease Research

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

4

1 reference

26 August 2017

256-269

1 reference

Diabetes and obesity: the twin epidemics

26 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Unraveling the links between diabetes, obesity, and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Circulation and degradation of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Metabolic manipulation in ischaemic heart disease, a novel approach to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

Cardiovascular Events in Diabetic and Nondiabetic Adults With or Without History of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112440816

21 January 2018

Identifiers

DOI

10.1177/1479164112440816

1 reference

26 August 2017

1 reference